Investigational drug · Phase 3
co-administration of aztreonam
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
4
Any phase or sponsor naming "co-administration of aztreonam"
First trial start
2023
May 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "co-administration of aztreonam", any sponsor or status.
Conditions studied
As listed on its trial records.
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Complicated Intra-abdominal Infection
- cUTI
- AP
Approved drugs for the same conditions: Urinary tract infection · Pneumonia · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "co-administration of aztreonam" as an intervention, largest first.
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
- P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant EnterobacteralesPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05905055 · 126 participants · Start Sep 22, 2023 · Primary completion Sep 1, 2025
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; Hospital-acquired Bacterial Pneumonia and 2 more
Sites: Changsha, China; Chongqing, China; Fuyang, China · 54 sites in all
Spero TherapeuticsIndustry
NCT03376529 · 27 participants · Start Nov 10, 2017 · Primary completion Dec 19, 2017
Drug: SPR741; Ceftazidime and 2 more · For: Healthy Volunteers
Sites: Merthyr Tydfil, United Kingdom
- Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative BacteriaPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT03580044 · 15 participants · Start Dec 25, 2020 · Primary completion Jan 23, 2023
Drug: BAT · For: Serious Bacterial Infection
Sites: Tucson, Arizona; Córdoba, Argentina; Shantou, China · 42 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Complicated Urinary Tract Infection
- co-administration of cefepimePhase 32 trials
Meiji Seika Pharma Co., Ltd. · Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia
- nacubactamPhase 32 trials
Meiji Seika Pharma Co., Ltd. · Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia
- antibioticsPhase 23 trials
TenNor Therapeutics (Zhongshan) Limited · Prosthetic Joint Infection (PJI), Periprosthetic Joint Infection (PJI), Acute Pyelonephritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.